Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells

Molecular Cancer Research

Volumn 4, Issue 2, 2006, Pages 113-123

  Rokhlin, Oskar W ^a   Glover, Rebecca B ^a   Guseva, Natalya V ^a   Taghiyev, Agshin F ^a   Kohlgraf, Karl G ^a   Cohen, Michael B ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; DACTINOMYCIN; DOXORUBICIN; HISTONE DEACETYLASE INHIBITOR; PROTEASOME; TRICHOSTATIN A;

ARTICLE; BREAST CANCER; CANCER CELL; CELL DEATH; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CASPASES; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYSTEINE PROTEINASE INHIBITORS; DOXORUBICIN; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENZYME ACTIVATION; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; LEUPEPTINS; LUCIFERASES; MALE; MICE; PROMOTER REGIONS (GENETICS); PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33645125545     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-05-0085     Document Type: Article

References (39)

1. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002;1:287-99.
2. Richon VM, Emiliani S, Verdin E, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A 1998;95:3003-7.
3. Butler LM, Agus DB, Scher HI, et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 2000;60:5165-70.
4. Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 2003;4:13-8.
5. Peart MJ, Smyth GK, van Laar RK, et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci U S A 2005;102:3697-702.
6. Insinga A, Monestiroli S, Ronzoni S, et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 2005;11:71-6.
7. Nebbioso A, Clarke N, Voltz E, et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 2005;11:77-84.
8. Ruefli AA, Ausserlechner MJ, Bernhard D, et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci U S A 2001;98:10833-8.
9. Peart MJ, Tainton KM, Ruefli AA, et al. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 2003;63:4460-71.
10. Nelson WG, De Marzo AM, Isaacs WB. Mechanisms of disease: prostate cancer. N Engl J Med 2003;349:366-81.
11. Linja MJ, Savinainen KJ, Saramaki OR, Tamella TLJ, Vessella RL, Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001;61:3550-5.
12. Chen CD, Welsbie DS, Tran C. et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-9.
13. 3 and its 19-norhexafluoride analogs in combination with either sodium butyrate or trichostatin A. Oncogene 2001;20:1860-72.
14. Korkmaz CG, Fronsdal K. Zhang Y, Lorenzo PI, Saatcioglu F. Potentiation of androgen receptor transcriptional activity by inhibition of histone deacetylation-rescue of transcriptionally compromised mutants. J Endocrinol 2004;182:377-89.
15. Fronsdal K, Saatcioglu F. Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells. Prostate 2005;62:299-306.
16. Thelen P, Schweyer S, Hemmerlein B, Wuttke W, Seseke F, Ringert R-H. Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells. Int J Oncol 2004;24:25-31.
17. Rokhlin OW, Gudkov AV, Kwek S, Glover RA, Gewies AS, Cohen MB. p53 is involved in tumor necrosis factor-α-induced apoptosis in the human prostatic carcinoma cell line LNCaP. Oncogene 2000;19:1959-68.
18. Rokhlin OW, Bishop GA, Hostager BS, et al. Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res 1997;57:1758-68.
19. Rokhlin OW, Glover RA, Taghiyev AF, et al. Bisindolylmaleimide IX facilitates rumor necrosis factor receptor family-mediated cell death and acts as an inhibitor of transcription. J Biol Chem 2002;277:33213-9.
20. Rokhlin OW, Taghiyev AF, Guseva NV, Glover RA, Syrbu SI, Cohen MB. TRAIL-DISC formation is androgen-dependent in the human prostatic carcinoma cell line LNCaP. Cancer Biol Ther 2002;1:631-7.
21. Szelei J, Jimenez J, Soto AM, Luizzi MF, Sonnenscheim C. Androgen-induced inhibition of proliferation in human breast cancer MCF7 cells transfected with androgen receptor. Endocrinology 1997;138:1406-12.
22. Blankvoort BM, de Groene EM, van Meeteren-Kreikamp AP, Witkamp RF, Rodenburg RJT, Aarts JG. Development of an androgen reporter gene assay (ARLUX) utilizing a human cell line with an endogenously regulated androgen receptor. Anal Biochem 2001;298:93-102.
23. Chang B-D, Watanabe K, Broude EV, et al. Effects of p21 on cellular gene expression: implications for carcinogenesis, senescence, and age-related diseases. Proc Natl Acad Sci U S A 2000;97:4291-6.
24. WAF1/CIP1. Oncogene 1999;18:5381-92.
25. WAF1/CIP1 inhibits initiator caspase cleavage by TRAIL death receptor DR4. Biochem Biophys Res Commun 2000;269:179-90.
26. WAF1/CIP1 can protect human colon carcinoma cells against p53-dependent and p53 independent apoptosis induced by natural chemopreventive and therapeutic agents. Oncogene 2001;20:3387-98.
27. Seoane J, Le H-V, Massaque J. Myc suppression of the p21 Cip1 Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 2002;419:729-34.
28. Li Y, Dowbenko D, Lasky L. AKT/PKB phosphorylation of p21 Cip1/WAF1 enhances protein stability of p21 Cip1/WAF1 and promotes cell survival. J Biol Chem 2002;277:11352-61.
29. Javelaud D, Besancon F. Inactivation of p21 WAF1 sensitizes cells to apoptosis via an increase of both p14 ARF and p53 levels and an alteration of the Bax/Bcl-2 ratio. J Biol Chem 2002;277:37949-54.
30. Guseva NV, Taghiyev AF, Rokhlin OW, Cohen MB. Death receptor-induced cell death in prostate cancer. J Cell Biochem 2004;91:70-99.
31. Liao X, Tang S, Thrasher JB, Griebling T, Li B. Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer. Mol Cancer Ther 2005;4:1-11.
32. 1 arrest, but indispensable for apoptosis induced by sodium butyrate in MCF-7 breast cancer cells. Oncogene 2004;23:21-9.
33. Beuvink I, Boulay A, Fumagalli S, et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005;120:747-59.
34. Suzuki A, Kawano H, Hayashida M, Hayasaki Y, Tsutomi Y, Akahane K. Procaspase 3/p21 complex formation to resist Fas-mediated cell death is initiated as a result of the phosphorylation of p21 by protein kinase A. Cell Death Differ 2000;7:721-8.
35. Sasaki T, Kikuchi T, Yumoto N, Yoshimura N, Murachi T. Comparative specificity and kinetic studies on porcine calpain I and II with naturally occurring peptides and synthetic fluorogenic substrates. J Biol Chem 1984;259:12489-94.
36. Rokhlin OW, Cohen MB. Bisindolylmaleimide IX induces reversible and time-dependent tumor necrosis factor receptor family-mediated caspase activation and cell death. Cancer Biol Ther 2003;2:266-70.
37. Rokhlin OW, Taghiyev AF, Guseva NV, et al. Androgen regulates apoptosis induced by TNFR family ligands via multiple signaling pathways in LNCaP [advanced online publication]. Oncogene 2005;24:6773-84.
38. Rokhlin OW, Guseva NV, Taghiyev AF, Glover RA, Cohen MB. Multiple effects of TPCK on apoptotic pathways in human prostatic carcinoma cell lines. Cancer Biol Ther 2004;3:761-8.
39. Heisler LE, Evangelou A, Lew AM, Trachtenberg J, Elsholtz HP, Brown TJ. Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full length human androgen receptor. Mol Cell Endocrinol 1997;126:59-73.